Sorry, you need to enable JavaScript to visit this website.
  1. Home
  3. Science
  4. Clinical Trials
  5. Plain Language Study Results Summaries
  6. Safety And Tolerability Study Daily

Safety and Tolerability Study of Daily Dosing of Rimegepant in Episodic Migraine Prevention

A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention

Category & Conditions: Neurological Diseases and Conditions
Medicine: Nurtec® ODT (Rimegepant)
ClinicalTrials.gov Identifier (NCT): NCT05207865
Protocol ID: C4951011 (BHV3000-405)
DownloadPrint

Open Plain Language Summary Result:

Click here